MABA seeks to invest in companies the following characteristics
Strong, commercially-minded management team
Once the company has graduated from a lab research project and engaged at least one key commercially-focused leader, and once the company is focused on the commercialization of an identified asset.
Solutions that will change the standard of care
Beyond an incremental improvement, disruptive solutions will ultimately change the way practitioners practice medicine in their field
Regulated products, e.g., therapeutics, devices, diagnostics, some digital (therapeutics, biomarkers, etc.)
Large and growing addressable markets
Markets that can support a large exit, preferably by M&A
Angel friendly investments
Angel investors can achieve a return on their investment when they invest in successive rounds (often syndicated) that are traditionally well below $10 million each, and that total ~$30 million or less, before reaching an exit. These are the types of opportunities in which MABA seeks to participate. Rounds that are larger than $10 million, and funding requirements that exceed $40 million in total, to reach an exit, are more suited for venture capital (VC) than for angels, and ones that MABA seeks to avoid.
Our Investment Criteria
If you believe that your company meets our Investment Criteria,
please submit an Application for our group’s consideration.
Mid Atlantic Bio Angels group (MABA), is an angel investor group focused exclusively on new and emerging life science companies.
Membership in MABA is by invitation only, and is extended to active, accredited investors (life science angels) who wish to make investments in life science companies, as well as institutional investors and life science company venture arms wishing to invest alongside the angels.